Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the bonnet monkey model

Journal of Infectious Diseases

Volumn 187, Issue 8, 2003, Pages 1257-1263

  Ponnuraj, Esther M ^a   Springer, Jennifer ^a,c   Hayward, Anthony R ^a,d   Wilson, Harry ^b   Simoes, Eric A F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Providence Memorial Hospital   (United States)

^c Gambro BCT   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; LUNG DISEASE; MACROPHAGE; MONKEY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VERO CELL; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; HUMANS; MACACA RADIATA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; U937 CELLS; VACCINES, INACTIVATED; VIRUS REPLICATION;

EID: 0037446912     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374604     Document Type: Article

References (40)

1. Kim HW, Leikin SL, Arrobio JO, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976; 10:75-8.
2. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-48.
3. Chin J, Magoffin RL, Sheaarer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-63.
4. Kapikan AZ, Mitchell RH, Chanock RM, Shved RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated vaccine. Am J Epidemiol 1969; 89:405-21.
5. Simoes EAF, Hayward AR, Ponnuraj EM, et al. Respiratory syncytial virus (RSV) infects the Bonnet monkey: Macaca radiata. Pediatr Dev Pathol 1999; 2:316-26.
6. Ponnuraj EM, Hayward AR, Raj A, Wilson H, Simoes EAF. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine. J Gen Virol 2001; 82:2663-74.
7. Gimenez HB, Chisholm S, Doran J, Cash P. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin Diagn Lab Immunol 1996; 3:280-6.
8. Detre K, White C. The comparison of two Poisson-distributed observations. Biometrics 1970; 26:851-4.
9. + T cells. J Virol 1992; 66:7444-51.
10. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage. Rev Infect Dis 1989; 11:S830-9.
11. Gollins SW, Porterfield JS. Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol 1984; 65:1261-72.
12. Domurat FR, Roberts NJ, Walsh EE, Dugan R. Respiratory syncytial virus infection in human mononuclear leukocyte in vitro and in vivo. J Infect Dis 1985; 152:895-902.
13. O'Donnell DR, McGarvey MJ, Tully JM, Balfour-Lynn IM, Openshaw JM. Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. J Pediatr 1998; 133:272-4.
14. Connors M, Collins PI, Firestone CY, et al. Cotton rats previously immunized with chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 1992; 10:475-84.
15. Wahl SM, Orenstein JM, Smith PD. Macrophage functions in HIV-1 infection. In: Gupta S, ed. Immunology of HIV infection. New York: Plenum Press, 1996:303-36.
16. Lukashevich IS, Maryankova R, Vladyko AS, et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol 1999; 59:552-60.
17. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 1996; 70:2208-14.
18. Hober D, Delannoy AS, Benyoucef S, De Groote D, Wattre P. High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol Immunol 1996; 40:569-73.
19. Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 1997; 71:4226-32.
20. Hayes PJ, Scott R, Wheeler J. In vivo production of tumor necrosis factor a and interlukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus. J Med Virol 1994; 42:323-9.
21. Panuska JR, Hertz MI, Taraf H, Villani A, Cirino NM. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am Rev Respir Dis 1992; 145:934-9.
22. Sharma R, Woldehiwet Z. Re-infection of lambs with bovine respiratory syncytial virus. Res Vet Sci 1992; 52:72-7.
23. Midulla F, Huang YT, Gilbert IA, Cirino NM, McFadden ER Jr, Panuska J. Respiratory syncytial virus infection of human cord and adult blood monocytes and alveolar macrophages. Am Rev Respir Dis 1989; 140:771-7.
24. Sharma R, Woldehiwet Z. Replication of bovine respiratory syncytial virus in ovine peripheral blood lymphocytes and monocytes in vitro. Vet Microbiol 1996; 48:125-34.
25. Osiowy C, Horne D, Anderson R. Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin Diagn Lab Immunol 1994; 1:670-7.
26. Murphy BR, Prince GA, Walsh EE, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986; 24:197-202.
27. Kakuk TJ, Soike K, Brideau RJ, et al . A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993; 167:553-61.
28. DeSwart RL, Kuiken T, Timmerman HH, et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 2002; 76:11561-9.
29. Techaarpornkul S, Collins PL, Peeples ME. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 2002; 294:296-304.
30. Kirlov LR, Anderson LJ, Marcoux L, Bonagura VR, Wedgwood JF. Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines. J Infect Dis 1989; 160:777-82.
31. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
32. Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 2001; 20:954-60.
33. Ottolini MG, Curtis SR, Mathews A, Ottolini SR, Prince GA. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 2002; 29:117-20.
34. Young J. Development of a potent respiratory syncytial virus specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 2002; 96:S31-5.
35. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102:531-7.
36. Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196:859-65.
37. Ananaba GA, Anderson LJ. Antibody enhancement of respiratory syncytial virus stimulation of leukotriene production by a macrophage-like cell line. J Virol 1991; 65:5052-60.
38. Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 1988; 24:504-7.
39. Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002; 282:L1143-50.
40. Graham BS, Rutigliano JA, Johnson TR. Respiratory syncytial virus immunobiology and pathogenesis. Virology 2002; 297:1-7.